Samsung Biologics

Samsung Biologics, a Pharmaceutical Preparation Manufacturing company headquartered in South Korea, reported total carbon emissions of approximately 636.2 million kg CO2e in 2024. This figure includes Scope 1 emissions of 71.97 million kg CO2e, Scope 2 emissions (market-based) of 115.83 million kg CO2e, and Scope 3 emissions of 448.41 million kg CO2e. This represents a decrease from 2023, where total emissions were approximately 696.38 million kg CO2e, comprising Scope 1 emissions of 69.26 million kg CO2e, Scope 2 emissions (market-based) of 113.31 million kg CO2e, and Scope 3 emissions of 513.80 million kg CO2e.

Looking further back, in 2022, Samsung Biologics reported total emissions of approximately 946.21 million kg CO2e, with Scope 1 at 54.58 million kg CO2e, Scope 2 (market-based) at 99.92 million kg CO2e, and Scope 3 at 791.71 million kg CO2e. In 2021, the company's total emissions were approximately 1.05 billion kg CO2e (derived from Scope 1 emissions of 44.06 million kg CO2e, Scope 2 emissions of 86.87 million kg CO2e, and Scope 3 emissions of 917.23 million kg CO2e). In 2020, total reported Scope 1 and Scope 2 emissions were 124.81 million kg CO2e, and Scope 3 emissions were 64.17 million kg CO2e. For 2019, only Scope 1 and Scope 2 emissions were reported, totalling 119.79 million kg CO2e. Similarly, in 2018, Scope 1 and Scope 2 emissions were 116.58 million kg CO2e, and in 2017, they were 85.31 million kg CO2e.

Samsung Biologics is committed to achieving net-zero emissions by 2050 or earlier. As part of this commitment, the company has set several ambitious targets, using a 2022 baseline. These include an absolute reduction target for Scope 1 emissions of 32% by 2030 and 62% by 2040. Additionally, they aim to reduce suppliers' emissions by 36% by 2030 and 73% by 2040.